Hostname: page-component-6bb9c88b65-x9fsb Total loading time: 0 Render date: 2025-07-23T14:58:10.790Z Has data issue: false hasContentIssue false
  • English
  • Français

Early outcomes of Myval™ Octacor transcatheter pulmonary valve implantation in dysfunctional right ventricular outflow tract conduits and pulmonary valve bioprostheses: a single-centre UK experience

Published online by Cambridge University Press:  16 July 2025

Mohammed Kamal Badawy Open the ORCID record for Mohammed Kamal Badawy [Opens in a new window] ,
Atul Kalantre  and
Marinos Kantzis Open the ORCID record for Marinos Kantzis [Opens in a new window]
Mohammed Kamal Badawy*
Affiliation:
East Midlands Congenital Heart Centre, University Hospitals of Leicester, Leicester, UK
Atul Kalantre
Affiliation:
East Midlands Congenital Heart Centre, University Hospitals of Leicester, Leicester, UK
Marinos Kantzis
Affiliation:
East Midlands Congenital Heart Centre, University Hospitals of Leicester, Leicester, UK
*
Corresponding author: Mohammed Kamal Badawy; Email: mohammed.badawy@doctors.net.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Transcatheter pulmonary valve implantation has emerged as a minimally invasive and preferred therapeutic option for patients with dysfunction of previously repaired right ventricular outflow tracts. The Myval™ Octacor valve is a new device designed for this purpose, though limited reports exist regarding its use in the pulmonary position.

Aims:

To report the immediate and short-term outcomes of percutaneous pulmonary valve implantation using the Myval™ Octacor valve in patients with severe right ventricular–pulmonary artery conduit or pulmonary valve bioprosthesis dysfunction.

Methods:

This was a single-centre retrospective review of data obtained from case files.

Results:

The Myval™ Octacor valve was used in ten patients with a mean age of 34.5 ± 7.4 years. The median procedure duration and fluoroscopy time were 146 minutes and 30.5 minutes, respectively. The median Z-score for valves used was −0.5. The median right ventricular systolic pressure decreased from 68.5 mmHg pre-procedure to 33 mmHg post-procedure. The median peak instantaneous gradient across the right ventricular outflow tract or conduit decreased from 30 mmHg to 6.5 mmHg. There were no reported incidences of frame fracture, conduit rupture, device embolisation, or endocarditis.

Conclusion:

This is the first UK experience of using the new-generation Myval™ Octacor valve in percutaneous pulmonary valve implantation. The results demonstrate the valve’s safety and clinical efficacy, with favourable outcomes in terms of procedural success, haemodynamic improvement, and echocardiographic findings.

Keywords

pulmonary valve implantationMyval™ Octacoroutcomes

Information

Type
Original Article
Information
Cardiology in the Young , First View , pp. 1 - 7
Check for updates
Copyright
© The Author(s), 2025. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Kheiwa, A, Divanji, P, Mahadevan, VS. Transcatheter pulmonary valve implantation: will it replace surgical pulmonary valve replacement? Expert Rev Cardiovasc Ther 2018; 16: 197–207.10.1080/14779072.2018.1435273CrossRefGoogle ScholarPubMed
Bonhoeffer, P, Boudjemline, Y, Saliba, Z, et al. Percutaneous replacement of pulmonary valve in a right ventricle to pulmonary artery prosthetic conduit with valve dysfunction. Lancet 2000; 356: 1403–1405.10.1016/S0140-6736(00)02844-0CrossRefGoogle Scholar
Bonhoeffer, P, Boudjemline, Y, Qureshi, SA, et al. Percutaneous insertion of the pulmonary valve. J Am Coll Cardiol 2002; 39: 1664–1669.CrossRefGoogle ScholarPubMed
Hascoët, S, Acar, P, Boudjemline, Y. Transcatheter pulmonary valvulation: current indications and available devices. Arch Cardiovasc Dis 2014; 107: 625–634.10.1016/j.acvd.2014.07.048CrossRefGoogle ScholarPubMed
Driesen, BW, Warmerdam, EG, Sieswerda, GJ, et al. Percutaneous pulmonary valve implantation: current status and future perspectives. Curr Cardiol Rev 2019; 15: 262–273.10.2174/1573403X15666181224113855CrossRefGoogle ScholarPubMed
Baumgartner, H, De Backer, J, Babu-Narayan, SV, et al. 2020 ESC guidelines for the management of adult congenital heart disease. Eur Heart J 2021; 42: 563–645.10.1093/eurheartj/ehaa554CrossRefGoogle ScholarPubMed
García-Gómez, M, Fernández-Cordón, C, González-Gutiérrez, JC, et al. The novel balloon-expandable Myval transcatheter heart valve: systematic review of aortic, mitral, tricuspid and pulmonary indications. Rev Esp Cardiol (Engl Ed) 2025; 78: 447–464.10.1016/j.recesp.2024.09.013CrossRefGoogle ScholarPubMed
Montonati, C, Pellegrini, D, d’Atri, DO, et al. A novel balloon-expandable transcatheter aortic valve bioprosthesis: Myval and Myval Octacor. Expert Rev Cardiovasc Ther 2024; 22: 325–337.10.1080/14779072.2024.2375345CrossRefGoogle ScholarPubMed
Medicines and Healthcare products Regulatory Agency (MHRA). Guidance on the off-label use of medical devices. UK Government. Published 2014, last updated July 2023. Available at: https://www.gov.uk/government/publications/medical-devices-off-label-use.Google Scholar
Al Nasef, M, Erdem, A, Aldudak, B, et al. Multicenter experience for early and mid-term outcome of MyVal transcatheter pulmonary valve implantation. Pediatr Cardiol 2024; 45: 570–579.10.1007/s00246-023-03398-1CrossRefGoogle ScholarPubMed
Sivaprakasam, MC, Reddy, JRV, Gunasekaran, S, et al. Early multicenter experience of a new balloon expandable MyVal transcatheter heart valve in dysfunctional stenosed right ventricular outflow tract conduits. Ann Pediatr Cardiol 2021; 14: 293–301.10.4103/apc.apc_242_20CrossRefGoogle ScholarPubMed
Jose, J, Mandalay, A, Cholenahally, MN, et al. Safety and effectiveness of the novel Myval Octacor transcatheter heart valve in severe, symptomatic aortic valve stenosis – a real-world Indian experience (The OCTACOR India study). Cardiovasc Revasc Med 2024; 63: 1–7.10.1016/j.carrev.2024.01.016CrossRefGoogle ScholarPubMed
Sivaprakasam, MC, Arvind, A, Sridhar, A, Gunasekaran, S. First transcatheter pulmonary valve implantation – an Indian-made valve. IHJ Cardiovasc Case Rep CVCR 2020; 4: 13–16.Google Scholar
Nordmeyer, P, Ewert, M, Gewillig, M, et al. Acute and midterm outcomes of the post-approval MELODY registry: a multicentre registry of transcatheter pulmonary valve implantation. Eur Heart J 2019; 40: 2255–2264.10.1093/eurheartj/ehz201CrossRefGoogle ScholarPubMed
Hascoët, S, Bentham, JR, Giugno, L, et al. Outcomes of transcatheter pulmonary SAPIEN 3 valve implantation: an international registry. Eur Heart J 2024; 45: 198–210.10.1093/eurheartj/ehad663CrossRefGoogle ScholarPubMed
Odemis, E, Yenidogan, I. First experiences with Myval Transcatheter heart valve system in the treatment of severe pulmonary regurgitation in native right ventricular outflow tract and conduit dysfunction. Cardiol Young 2022; 32: 1609–1615.10.1017/S1047951121004650CrossRefGoogle ScholarPubMed
Shahanavaz, S, Qureshi, AM, Levi, DS, et al. Transcatheter pulmonary valve replacement with the melody valve in small diameter expandable right ventricular outflow tract conduits. JACC Cardiovasc Interv 2018; 11: 554–564.10.1016/j.jcin.2018.01.239CrossRefGoogle ScholarPubMed
Malekzadeh-Milani, S, Ladouceur, M, Patel, M, et al. Incidence and predictors of melody® valve endocarditis: a prospective study. Arch Cardiovasc Dis 2015; 108: 97–106.10.1016/j.acvd.2014.09.003CrossRefGoogle ScholarPubMed
Van Dijck, I, Budts, W, Cools, B, et al. Infective endocarditis of a transcatheter pulmonary valve in comparison with surgical implants. Heart 2015; 101: 788–793.10.1136/heartjnl-2014-306761CrossRefGoogle ScholarPubMed
Cheatham, JP, Hellenbrand, WE, Zahn, EM, et al. Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the US melody valve investigational device exemption trial. Circulation 2015; 131: 1960–1970.10.1161/CIRCULATIONAHA.114.013588CrossRefGoogle ScholarPubMed
Nordmeyer, J, Khambadkone, S, Coats, L, et al. Risk stratification, systematic classification, and anticipatory management strategies for stent fracture after percutaneous pulmonary valve implantation. Circulation 2007; 115: 1392–1397.10.1161/CIRCULATIONAHA.106.674259CrossRefGoogle ScholarPubMed
Patel, ND, Levi, DS, Cheatham, JP, et al. Transcatheter pulmonary valve replacement: a review of current valve technologies. J Soc Cardiovasc Angiogr Interv 2022; 1: 100452.Google ScholarPubMed
Shivaraju, A, Kodali, S, Thilo, C, et al. Overexpansion of the SAPIEN 3 Transcatheter heart valve: a feasibility study. J Am Coll Cardiol Intv 2015; 8: 2041–2043.10.1016/j.jcin.2015.10.006CrossRefGoogle ScholarPubMed
Sellers, SL, Sathananthan, J, Bouchareb, R, et al. Impact of over-expansion on SAPIEN 3 Transcatheter heart valve pericardial leaflets. Struct Heart 2020; 4: 491–500.Google Scholar
Houeijeh, A, Sudre, A, Juthier, F, Godart, F. Pulmonary valve replacement in a large and tortuous right ventricle outflow tract with a 32 mm Myval valve under local anaesthesia: challenges and technical considerations: a case report. Eur Heart J Case Rep 2023; 7: ytad322.10.1093/ehjcr/ytad322CrossRefGoogle Scholar